GRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Dec. 2023, Galera Therapeutics paid $0.23 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Galera Therapeutics spent $0.23 Mil on financial activities for the three months ended in Dec. 2023.
The historical data trend for Galera Therapeutics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galera Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 78.03 | 20.51 | 66.71 | 3.89 | 31.50 |
Galera Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Flow from Financing | Get a 7-Day Free Trial | 2.70 | 27.78 | 1.81 | 2.13 | -0.23 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Galera Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing | (A: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 29.299 | + | 0 | + | 0 | + | 0 | + | 0 | + | 2.197 |
= | 31.50 |
Galera Therapeutics's Cash from Financing for the quarter that ended in Dec. 2023 is:
Cash Flow from Financing | (Q: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | -0.232 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 |
= | -0.23 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galera Therapeutics (NAS:GRTX) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Galera Therapeutics's issuance of stock for the three months ended in Dec. 2023 was $-0.23 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Galera Therapeutics's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Galera Therapeutics's net issuance of debt for the three months ended in Dec. 2023 was $0.00 Mil. Galera Therapeutics received $0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Galera Therapeutics's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Galera Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Galera Therapeutics's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Galera Therapeutics received $0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Galera Therapeutics's other financing for the three months ended in Dec. 2023 was $0.00 Mil. Galera Therapeutics received $0.00 Mil on other financial activities.
Thank you for viewing the detailed overview of Galera Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark Bachleda | officer: Chief Commercial Officer | C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355 |
Chris Degnan | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Mel Sorensen | director, officer: President and CEO | 7 RAPPS RUN DRIVE, MALVERN PA 19355 |
Eugene P. Kennedy | officer: Chief Medical Officer | 2503 SOUTH LOOP DRIVE, AMES IA 50010 |
Linda West | director | C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355 |
Jennifer Evans Stacey | officer: See Remarks | AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401 |
Jon T Holmlund | officer: Chief Medical Officer | |
Lawrence M Alleva | director | 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Novo Holdings A/s | 10 percent owner, other: SEE REMARKS | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Joel F. Sussman | officer: Chief Accounting Officer | C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355 |
Novartis Bioventures Ltd | 10 percent owner | C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000 |
New Enterprise Associates 14, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Clarus Iv-a, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Blackstone Clarus Gp L.p. | 10 percent owner | C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154 |
Sofinnova Venture Partners Ix, L.p. | 10 percent owner | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
From GuruFocus
By Marketwired • 08-09-2023
By PurpleRose PurpleRose • 08-09-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By Value_Insider Value_Insider • 12-12-2022
By PurpleRose PurpleRose • 07-15-2022
By Marketwired • 10-31-2023
By PurpleRose PurpleRose • 07-15-2022
By sperokesalga sperokesalga • 02-15-2023
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 09-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.